Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
JDRF Celebrates Research Award Winners and Recognizes Type 1 Diabetes Research Leaders | ||
By: PR Newswire Association LLC. - 18 Apr 2024 | Back to overview list |
|
NEW YORK, April 18, 2024 /PRNewswire/ -- JDRF, the leading global type 1 diabetes (T1D) research and advocacy organization, proudly presented awards to five outstanding leaders in T1D research whose impact has pushed JDRF's mission forward. Award recipients include:
"Since our inception, JDRF's mission has been focused on accelerating research and breakthroughs to cure, prevent, and treat type 1 diabetes and its complications. Our progress has been driven by the exceptional work and commitment of T1D researchers across the globe," said JDRF Chief Scientific Officer Sanjoy Dutta, Ph.D. "It's an honor to recognize and celebrate these dedicated individuals for their leadership and clinical implementation in research and the tangible impacts they have had on their fields and the millions of people who live with or are at risk of T1D." George Eisenbarth Award for Type 1 Diabetes Prevention Dr. Moshe Phillip and Dr. Linda DiMeglio have led the development of international consensus guidance for monitoring of T1D in its early stages prior to clinical diagnosis. As chair and vice chair of this effort, they helped convene a broad range of global experts and co-led the writing of the guidance document, which will provide actionable information for healthcare providers to monitor early-stage T1D in the clinical setting. Dr. Phillip is the director of the Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes at Schneider Children's Medical Center, Petah Tikva, where he has served since 1997, and leads the Diabetes Technologies Center at the institute. Under Dr. Phillip's leadership, the institute was leading the first multinational multicenter study with automatic insulin delivery (AID) outside of a hospital. Dr. Phillip is currently engaged in studies for national screening of diabetes in the general population and in family members. He remains active in clinical and applied research, focusing on childhood diabetes and growth. In addition to maintaining an active clinical practice, Dr. DiMeglio serves as the Edwin Letzter Professor of Pediatrics at Indiana University School of Medicine and Chief of the Division of Pediatric Endocrinology and Diabetology at Riley Children's Health. She began her career with a JDRF career development award to support one of her first research projects on insulin pump therapy in very young children with diabetes. Now, she directs local and national research teams focused on preventing T1D, preserving beta cell function, and improving metabolic control and quality of life for persons living with the disease. JDRF Rumbough Award For over 20 years, Dr. Colin Dayan has been a leader in T1D immunotherapy research, and his work has been central to JDRF's research strategy and overall mission. He is leading efforts to bring teplizumab, the first disease-modifying therapy approved by the U.S. Food and Drug Administration that can delay clinical T1D in individuals in early stages, to Europe and the UK to expand treatment options available in these areas. He is a leading member of the JDRF-funded UK T1D Research Consortium, through which he has brought the research community together to accelerate critical research, leverage collective resources, and collaborate to improve T1D clinical trial delivery. Currently, Professor Dayan serves as chair of Clinical Diabetes and Metabolism and head of section at Cardiff University School of Medicine and as part-time senior clinical researcher in the Nuffield Department of Medicine at the University of Oxford. Dr. Robert Goldstein Award Dr. Kirstine Bell is a diabetes educator, dietitian, and the principal research fellow at the Charles Perkins Centre at the University of Sydney. She leads the Australian T1D National Screening Pilot, a national feasibility, acceptability, and cost-effectiveness program to determine the optimal method for routine, publicly funded national screening program for all Australian children. She has served in a critical role as a co-first author on the 2022 ISPAD Clinical Practice Consensus Guideline: Stages of T1D in children and adolescents. Mary Tyler Moore and S. Robert Levine, M.D., Excellence in Clinical Research Award Dr. Viral Shah is currently leading a JDRF-funded trial to examine the effects of semaglutide, a GLP-1 agonist, in people with T1D and hybrid closed-loop systems, and he recently published the first report on use of the GLP1-GIP agonist Mounjaro in T1D that demonstrated promising results. His research has also shown the association between time in range and retinopathy progression in T1D, which provides necessary evidence to support future therapy development. Dr. Shah is a professor of medicine in endocrinology and metabolism and the director of diabetes clinical research at the Center for Diabetes and Metabolic Diseases at Indiana University whose research focuses on improving glycemic control and reducing complications in people with T1D. JDRF Research award recipients were recognized at a ceremony in New York City earlier in April 2024. JDRF recognizes and appreciates all of the dedicated researchers who are committed to finding cures and improving the lives of those living with T1D. About JDRF About Type 1 Diabetes (T1D) Contact: View original content to download multimedia:https://www.prnewswire.com/news-releases/jdrf-celebrates-research-award-winners-and-recognizes-type-1-diabetes-research-leaders-302120537.html SOURCE JDRF International |
||
|
||
Copyright 2024 PR Newswire Association LLC. | Back to overview list |